SCHEMBL701012

SCHEMBL701012

CN1CCN(c2ccc(-c3ccc(/C=C4/C(=O)Nc5ccccc54)o3)cn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
PIM1 P11309 5/20 0.50
DYRK1A Q13627 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
THRB P10828 1/20 0.50
ALOX12 P18054 1/20 0.50
BRD4 O60885 1/20 0.47
CREBBP Q92793 1/20 0.47
PIM2 Q9P1W9 3/20 0.46
FLT3 P36888 1/20 0.46
PIM3 Q86V86 1/20 0.46
GSK3B P49841 1/20 0.45
TNKS O95271 1/20 0.43
RPS6KA3 P51812 1/20 0.42
PDGFRB P09619 2/20 0.41
PTPN1 P18031 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701013 1.00 POLB (0.54) POLBKMT2AMEN1PIM1DYRK1A
SCHEMBL10091728 0.87 PIM1 (0.59) POLBKMT2AMEN1PIM1PIM2
SCHEMBL10091625 0.85 PIM1 (0.55) POLBKMT2AMEN1PIM1DYRK1A
SCHEMBL10091626 0.82 PIM1 (0.60) POLBKMT2AMEN1PIM1DYRK1A
SCHEMBL10091686 0.77 PIM1 (0.65) POLBKMT2AMEN1PIM1DYRK1A
SCHEMBL701130 0.77 PIM1 (0.59) POLBKMT2AMEN1PIM1PIM2
SCHEMBL10091759 0.77 PIM1 (0.59) POLBKMT2AMEN1PIM1PIM2
SCHEMBL701129 0.77 PIM1 (0.59) POLBKMT2AMEN1PIM1PIM2
SCHEMBL10091611 0.77 PIM1 (0.46) POLBKMT2AMEN1PIM1DYRK1A
SCHEMBL10091613 0.76 PIM1 (0.63) POLBKMT2AMEN1PIM1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 POLB 2906/4885KMT2A 1375/4885MEN1 3039/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 POLB 2906/4885KMT2A 1375/4885MEN1 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.